

CHEST[®]

THE CARDIOPULMONARY
AND CRITICAL CARE JOURNAL

FOR PULMONOLOGISTS, CARDIOLOGISTS, CARDIOTHORACIC SURGEONS,
CRITICAL CARE PHYSICIANS, AND RELATED SPECIALISTS

Influence of Lung Parenchymal Destruction on the Different Indexes of the Methacholine Dose-Response Curve in COPD Patients

Gert T. Verhoeven, Anton F.M. Verbraak, Sandra Boere-van der Straat, Henk C. Hoogsteden and Jan M. Bogaard
Chest 2000;117:984-990
DOI: 10.1378/chest.117.4.984

This information is current as of December 4, 2006

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.chestjournal.org/cgi/content/full/117/4/984>

CHEST is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright 2005 by the American College of Chest Physicians, 3300 Dundee Road, Northbrook IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder. ISSN: 0012-3692.

A M E R I C A N C O L L E G E O F
 **C H E S T**
P H Y S I C I A N S

Influence of Lung Parenchymal Destruction on the Different Indexes of the Methacholine Dose-Response Curve in COPD Patients*

Gert T. Verhoeven, MD; Anton F.M. Verbraak, PhD; Sandra Boere-van der Straat; Henk C. Hoogsteden, MD, PhD; and Jan M. Bogaard, PhD

Study objectives: The interpretation of nonspecific bronchial provocation dose-response curves in COPD is still a matter of debate. Bronchial hyperresponsiveness (BHR) in patients with COPD could be influenced by the destruction of the parenchyma and the augmented mechanical behavior of the lung. Therefore, we studied the interrelationships between indexes of BHR, on the one hand, and markers of lung parenchymal destruction, on the other.

Patients and methods: COPD patients were selected by clinical symptoms, evidence of chronic, nonreversible airways obstruction, and BHR, which was defined as a provocative dose of a substance (histamine) causing a 20% fall in FEV₁ (PC₂₀) of ≤ 8 mg/mL. BHR was subsequently studied by methacholine dose-response curves to which a sigmoid model was fitted for the estimation of plateau values and reactivity. Model fits of quasi-static lung pressure-volume (PV) curves yielded static lung compliance (Cstat), the exponential factor (KE) and elastic recoil at 90% of total lung capacity (P90TLC). Carbon monoxide (CO) transfer was measured with the standard single-breath method.

Results: Twenty-four patients were included in the study, and reliable PV data could be obtained from 19. The following mean values (\pm SD) were taken: FEV₁, $65 \pm 12\%$ of predicted; reversibility, $5.6 \pm 3.1\%$ of predicted; the PC₂₀ for methacholine, 4.3 ± 5.2 mg/mL; reactivity, $11.0 \pm 5.6\%$ FEV₁/doubling dose; plateau, $48.8 \pm 17.4\%$ FEV₁; transfer factor, $76.7 \pm 17.9\%$ of predicted; transfer coefficient for carbon monoxide (KCO), $85.9 \pm 22.6\%$ of predicted; Cstat, 4.28 ± 2.8 kPa; shape factor (KE), 1.9 ± 1.5 kPa; and P90TLC, 1.1 ± 0.8 kPa. We confirmed earlier reported relationships between Cstat, on the one hand, and KE ($p < 0.0001$), P90TLC ($p = 0.0012$), and KCO percent predicted ($p = 0.006$), on the other hand. The indexes of the methacholine provocation test were not related to any parameter of lung elasticity and CO transfer.

Conclusion: BHR in COPD patients who smoke most probably is determined by airways pathology rather than by the augmented mechanical behavior caused by lung parenchymal destruction.

(CHEST 2000; 117:984-990)

Key words: bronchial provocation tests; COPD; dose-response relationship; forced expiratory flow rates; human; lung compliance; lung volume measurements; methacholine bromide/diagnostic use; pulmonary diffusing capacity

Abbreviations: BHR = bronchial hyperresponsiveness; CO = carbon monoxide; Cstat = static lung compliance; FRC = functional residual capacity; IVC = inspiratory vital capacity; KCO = transfer coefficient for carbon monoxide; KE = shape factor; LE = linear-exponential; PC₂₀ = provocative concentration of a substance causing a 20% fall in FEV₁; P90TLC = elastic recoil pressure at 90% of total lung capacity; PV = pressure-volume; TLC = total lung capacity; TLCO = transfer factor for carbon monoxide.

Bronchial hyperresponsiveness (BHR) is present in patients with asthma and COPD.¹ Approximately half of the subjects with COPD in a general

population have BHR.² In the Lung Health Study,³ BHR was noted in 85.1% of the women and 58.9% of the men with mild-to-moderate airflow limitation. The estimation of BHR is important for the diagnosis of asthma and for determining asthma severity, whereas the meaning of BHR for the clinical management of COPD is still unclear.⁴ COPD patients with BHR appear to be prone to a more rapid decline of their FEV₁.⁵

Clinical studies suggest that BHR in patients with COPD differs from BHR in patients with asthma.⁶⁻⁹ For example, in patients with COPD, BHR for

*From the Department of Pulmonary and Intensive Care Medicine, University Hospital Dijkzigt, Erasmus Medical Center, Rotterdam, The Netherlands.

This study was supported by the Netherlands Asthma Foundation and Glaxo-Wellcome, The Netherlands.

Manuscript received March 31, 1999; revision accepted October 27, 1999.

Correspondence to: Gert T. Verhoeven, MD, Department of Pulmonary and Intensive Care Medicine, University Hospital Dijkzigt, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands; e-mail: Verhoeven@lond.azr.nl

physiologic stimuli (eg, cold air) usually is not found in the presence of BHR for pharmacologic agents (eg, histamine). In patients with asthma, both types of stimuli cause bronchoconstriction.^{6,7} The explanation for these differences might be found in the different pathologic changes in the airways and in the lung parenchyma of asthma and COPD patients.¹ The main and clearest difference between asthma and COPD is destruction of the lung parenchyma in COPD, leading to emphysema and loss of lung elasticity. In patients with COPD, compared to those with asthma, there is a relationship between baseline FEV₁ and the level of BHR.^{8,9} The FEV₁ is, however, not a good predictor of the amount of parenchymal destruction and loss of elastic recoil.^{10–13} The most reliable test for lung elasticity is the direct estimation of quasi-static esophageal pressure-volume (PV) curves.^{10,11,14} The destruction of parenchymal tissue also is shown by the impairment of carbon monoxide (CO) transfer.^{15–18} We performed these lung function tests in COPD patients who smoked, who fulfilled the established clinical and functional criteria for COPD, and who also had a provocative concentration of a substance (histamine) causing a 20% fall in FEV₁ (PC₂₀) of ≤ 8 mg/mL. In subsequent methacholine dose-response curves, not only PC₂₀ (sensitivity) but also maximal bronchoconstriction (plateau) and the slope of the curve (reactivity) were estimated, because these factors should yield additional information on the causative mechanisms of BHR.¹⁹

The aim of our study was to investigate the influence of the impairment of lung parenchymal structure on BHR by the estimation of the interrelationships between indexes related to lung parenchymal destruction (lung elasticity and CO transfer) and indexes from methacholine log-dose response curves.

MATERIALS AND METHODS

COPD patients were recruited according to generally accepted clinical and functional criteria.²⁰ The inclusion criteria were the following: chronic productive cough; age between 40 and 70 years; current smokers; negative skin tests for standard inhalation allergens; FEV₁ or FEV₁/inspiratory vital capacity (IVC) ratio $\leq 70\%$ of the predicted normal value; reversibility of FEV₁ of $< 10\%$ predicted after 750 μg terbutaline administered by metered-dose inhalation; and nonspecific BHR, defined by a PC₂₀ for histamine of ≤ 8 mg/mL. Exclusion criteria were the following: a history of asthma; complaints of wheezing; radiographic signs of bullous emphysema; recent respiratory tract infection; and recent or concurrent usage of anti-inflammatory drugs. Eligible patients refrained from oral anti-inflammatory medication at least 3 months and from inhaled glucocorticoids for at least 6 weeks before the start of the study.

The study was approved by the Medical Ethics Committee of the University Hospital Dijkzigt, and written informed consent was obtained from all participants.

Functional tests included the following: spirometry (total lung capacity [TLC], functional residual capacity [FRC], RV, IVC, FEV₁); reversibility test (FEV₁ percent predicted); single-breath CO transfer (transfer factor of the lung for CO [TLCO] and transfer coefficient for CO [KCO]); and PV curves. Spirometry was measured with the multiple-breath, closed Helium wash-in method, using a water-sealed spirometer (model D53R; Lode; Groningen, The Netherlands) and with the patient in sitting position. The lung volumes were corrected to body temperature and ambient pressure, saturated with water vapor. All reference values were derived from the standards of the European Community for Steel and Coal.^{21,22}

Histamine and methacholine provocation tests were performed according to the 2-min tidal breathing method that was first described by Cockcroft et al.^{23,24} The PC₂₀ for histamine was used as an inclusion criterion. Because of lesser side effects, methacholine was used for obtaining as complete as possible dose-response curves.²⁵ After inhalation of an isotonic saline solution, doubling concentrations of histamine-sulfate or acetyl- β -methylcholine-bromide were administered, starting with doses of 0.03 mg/mL. Methacholine was prepared by our hospital pharmacy department. Solutions were stored at 4°C and were used at room temperature. Aerosols were generated by a nebulizer (model 646; DeVilbiss Co; Somerset, PA) (measured output, 0.13 mL/min) and were inhaled by tidal breathing over a 2-min period at 5-min intervals. The response to methacholine or histamine was measured as the change in FEV₁ expressed as a percentage of the initial value. The histamine provocation test was interrupted if a 20% fall in FEV₁ occurred before or at a dose of 8 mg/mL. The methacholine tests were continued up to a concentration of 256 mg/mL but were interrupted if the FEV₁ fell by $> 60\%$ or if unpleasant side effects occurred.

From the methacholine provocation tests, the log₂ concentration and the measured percentage of changes in FEV₁ were imported to a computer program that fitted a sigmoid function (cumulative Gaussian distribution) to the data.²⁶ Reactivity (the slope of the curve), and plateau values (maximal bronchoconstriction) were taken from this model fit, whereas the PC₂₀ was calculated from the measured data by linear interpolation of adjacent data points.

The lung elasticity measurements were performed immediately after the reversibility test. This sequence was chosen for reasons of standardization and in order to minimize the potentially disturbing effect of airway closure on lung elasticity. Quasi-static deflation exercises were performed according to the method that has been described before.²⁷ In short, the transpulmonary pressure was measured via a transducer (model P45; Validyne Engineering Corp; Northridge, CA) coupled to a balloon that was positioned in the lower third of the esophagus. The simultaneous recording of volume changes was obtained during a slow expiration (ie, expiration not exceeding 0.3 L/s). Selected curves were smoothed by drawing a line by hand through catarcotic points of the cardiac pulsations on the curve. Volume data were obtained at equal transpulmonary pressure intervals, yielding an average of 10 to 30 data points up to the TLC level. A linear-exponential (LE) and an exponential model were fitted to the measured data. The LE model gave the most accurate fit to experimental curves and was, therefore, used for the estimation of static lung compliance (Cstat) and volume-dependent recoil pressures.^{27,28} For this fit, the curve was considered to be composed of a linear part, from the first data points on starting at the FRC level, and an exponential part, starting at the higher volume level. Cstat was obtained from the linear part if four or more data points contributed to that part. In a minority of cases, we calculated Cstat by hand as the slope between FRC and FRC + 0.5 L. The elastic recoil pressure at 90% of TLC (P90TLC) also was derived from the LE model fit. This pressure

index was considered to be the elastic recoil index with the lowest variation coefficient.²⁹ Additionally, we prefer to use the P90TLC values above the recoil pressure at TLC because P90TLC is less dependent on inspiratory muscle force. The shape factor (KE) was determined from the following generally used exponential equation:

$$V = V_{\max}\{1 - \exp[KE(P - P_0)]\}$$

where V_{\max} is the asymptotic value (in liters) and P_0 is the intercept with the P axis at $V = 0$ kPa.

KE can be considered as an elasticity index, independent of lung size.²⁸ For the fit with the exponential model, we used the same (measured) input data as for the LE model fit. KE was considered as an additional elasticity index.

Linear regression analysis between variables, pairwise multivariate correlation, and statistical significance were calculated with the use of a package of statistical software (Statistical Graphics Corp; Rockville, MD). Test results were considered statistically significant at $p < 0.05$.

RESULTS

Twenty-four patients were included in the study. From 19 patients, we obtained reliable PV curves; the remaining patients did not tolerate the esophagus balloon long enough or showed effects of swallowing that hampered an accurate interpretation of the data. The mean age of the patients was 56 years (Table 1). The mean FEV₁ was 65% of predicted. One patient had an FEV₁ > 70% of predicted but was included because his FEV₁/IVC ratio was 0.51. The mean reversibility of FEV₁ after terbutaline inhalation was 5.6%. Four patients showed no reversibility at all.

The patients had moderate or severe BHR (Table 1). The mean PC₂₀ for methacholine was higher than that for histamine (4.3 vs 1.7 mg/mL, respectively). This difference also was reported in an earlier study

of smokers with mild chronic airflow limitation.³⁰ After correction for the difference in molecular-weight (1 mg of the bromide compound is equivalent to 0.82 mg of the chloride compound), the corrected mean bromide value of the PC₂₀ became 3.5 mg/mL.

The mean plateau value was 48.8% of the FEV₁. In Figure 1, we present a curve in which the fitted plateau is almost equal to the measured data (Fig 1, *top*) and a curve in which the plateau value is derived from extrapolation (Fig 1, *bottom*). If the experimental plateau estimate was defined by the mean value of the last two provocative concentrations with a variation of < 5%, we observed that the fitted plateau was almost equal to the experimental plateau estimate in 13 of the 24 dose-response curves.

Cstat ranged from 1.06 to 10.52 kPa, which indicates a range from moderately low to clearly increased if a normal range of 1.5 to 2.5 kPa is taken into account.²¹ Mean Cstat was 4.6 kPa (Table 1). TLCO was between 34% of predicted and 106% of predicted, and KCO ranged from low (43% of predicted) to higher than normal (139% of predicted).

Statistically significant correlations existed among all the parameters of the PV curve (Table 2). The strongest correlation was between Cstat and KE ($R = 0.81$; $p < 0.0001$). The KCO percent predicted correlated strongly with Cstat ($R = -0.60$; $p = 0.006$; Table 2) but not with KE and P90TLC. The TLCO percent predicted showed no significant correlation with Cstat, KE, or P90TLC.

The indexes of BHR (PC₂₀, reactivity, and plateau value) were tested for correlation with the indexes of the PV curve (Cstat, KE, and P90TLC), CO transfer (TLCO and KCO), and FEV₁. In Table 3, we present the correlations between Cstat and the BHR in-

Table 1—Smoking Habits, FEV₁, Reversibility, BHR, CO Transfer, and Lung Elasticity Data

Data	No. of Patients	Mean ± SD	Median	Range
Age, yr	24	55.5 ± 8.5	54	42–69
Actual smoking, cigarettes/d	24	15.6 ± 6.8	13	6–30
Pack-years	24	23 ± 10.5	23	5–50
FEV ₁ , % predicted	24	64.5 ± 11.9	65	34–93
Reversibility, % predicted	24	5.6 ± 3.1	5.5	0–9.8
PC ₂₀				
Histamine	24	1.66 ± 2.00	0.87	0.11–8
Methacholine	24	4.27 ± 5.2	1.46	0.4–17.4
log ₂ PC ₂₀ methacholine	24	1.07 ± 1.74	0.53	–1.3–4.1
Reactivity, % FEV ₁ /doubling dose	24	11.0 ± 5.6	8.98	3.9–26.8
Plateau, %FEV ₁	24	48.8 ± 17.4	48.3	20.8–95.7
Cstat, kPa	19	4.6 ± 2.8	4.1	1.1–10.5
KE, kPa	19	2.5 ± 1.5	2.2	0.7–6.3
P90TLC, kPa	19	1.1 ± 0.8	0.8	0.4–2.7
TLCO, % predicted	24	76.7 ± 17.9	75	34–106
KCO, % predicted	24	85.9 ± 22.6	86	43–139




FIGURE 1. Two examples of sigmoid fitting of the methacholine provocation tests. *Top*: the measured data (◆) are almost equal to the fitted plateau. *Bottom*: the measured data (■) show that the plateau was not reached during the test.

dexes. No significance was found and no significance was found for the additional elasticity indexes and diffusion parameters.

There was a significant correlation between the FEV₁ percent predicted, on the one hand, and log₂ PC₂₀ for histamine and log₂ PC₂₀ for methacholine, on the other hand ($R = 0.44$, $p = 0.024$; and $R = 0.46$, $p = 0.023$, respectively; Table 3). There

Table 3—Correlations of the Indexes of BHR With Quasi-Static Compliance and FEV₁ by Pairwise Multivariate Analysis*

Variable 1	Variable 2	No. of Patients	R Value	p Value
PC ₂₀ hist	Cstat	19	0.282	0.24
PC ₂₀ meth	Cstat	19	0.061	0.82
Reactivity	Cstat	19	0.291	0.24
Plateau	Cstat	19	0.321	0.19
PC ₂₀ hist	FEV ₁	24	0.483	0.01
PC ₂₀ meth	FEV ₁	24	0.470	0.02
Reactivity	FEV ₁	24	-0.522	0.0075
Plateau	FEV ₁	24	-0.194	0.35

*hist = histamine; meth = methacholine.

was also a significant (negative) correlation between the FEV₁ percent predicted and reactivity ($R = -0.52$; $p = 0.008$; Table 3). The correlation between the FEV₁ percent predicted and the plateau value was not significant (Table 3).

Because smoking is the most important risk factor for emphysema, we looked at paired correlations among smoking data, CO transfer, and indexes of the PV curve. There was a significant correlation only between KE and the actual number of cigarettes smoked per day ($R = 0.53$; $p = 0.019$; Table 2).

DISCUSSION

The aim of our investigation was to study the interrelationships among indexes describing BHR, lung elasticity, and CO transfer in patients with COPD. For the estimation of BHR and the degree of impairment of lung mechanics, detailed information was obtained by fitting models of methacholine dose-response curves and quasi-static PV curves.

Several mechanisms have been proposed for explaining enhanced bronchoconstriction as a reaction to inhaled stimuli.^{1,19,31} Detailed analysis of methacholine log-dose response curves is supposed to offer additional information on the causative mechanisms

Table 2—Correlations of the Indexes of the PV Curves, CO Transfer, and Smoking by Pairwise Multivariate Analysis*

Variable 1	Variable 2	No. of Patients	R Value	p Value
Cstat	KE	19	0.821	< 0.0001
Cstat	P90TLC	19	-0.687	0.0012
TLCO, % predicted	Cstat	19	-0.290	0.23
TLCO, % predicted	KE	19	-0.254	0.29
TLCO, % predicted	P90TLC	19	0.123	0.62
KCO, % predicted	Cstat	19	-0.604	0.006
KCO, % predicted	KE	19	-0.414	0.077
KCO, % predicted	P90TLC	19	0.438	0.061
KE	Act smoking	19	0.534	0.019

*Act smoking = actual smoking (cigarettes/day).

of BHR.¹⁹ PC₂₀ and reactivity are considered to be determined by prejunctional mechanisms, and the plateau value is more dependent on postjunctional mechanisms.¹⁹ In patients with COPD, both prejunctional mechanisms (*ie*, epithelial damage, neural control, and inflammation) and postjunctional mechanisms (*ie*, loss of lung elasticity, swelling of airway wall, and intraluminal secretions) can be responsible for the occurrence of BHR. Because lung elasticity in stable patients with asthma is not appreciably disturbed, this would be an attractive explanation for the occurrence of BHR in patients with COPD and to relate it to the loss of elastic recoil. Theoretically, a decrease in lung elasticity can facilitate an amplified bronchomuscular response.³¹

First, we have studied the functional indexes of lung parenchymal destruction.

Some degree of emphysema, which is present in patients with mild COPD, already influences the PV relationships.^{10,11,14} A PV curve can be obtained with relatively simple techniques but has the disadvantage of being an invasive test. The reproducibility of estimates, especially of KE, was reported to be good, at least for healthy adults.^{29,32,33} KE was found to be a good indicator for the presence of mild emphysema.^{10,15,32} We found that Cstat and P90TLC from the LE model fit and KE from the exponential model fit correlated well with each other, indicating that these indexes were linked to elastic properties of the lung (Table 2).

An additional index of lung parenchymal destruction is CO diffusion. Berend et al¹⁶ were the first to report a correlation between CO transfer and severity of emphysema. Others have confirmed the relationship between emphysema and KCO.^{15,17,18} We found also a significant correlation of Cstat with KCO (Table 2). KCO can be considered as an index, related to structural aspects of the lung parenchyma, whereas TLCO is a measure of overall gas transport.

In this study, we also tested the indexes of the impairment of lung parenchymal structure for correlation with cigarette smoke exposure, pack-years and actual smoking. There was a significant correlation of KE only with actual smoking (Table 2). There are few data about the correlation of smoking with parenchyma impairment. In one study, there was no detectable effect of smoking on lung elastic recoil in healthy men.³⁴ Other investigators have reported a quantitative relationship between the total exposure to cigarette smoke and both alveolar and airway pathologic features in a necropsy study.³⁵ So, although the assumption is plausible that there is a relationship between cigarette smoke exposure and loss of elastic recoil, it is not yet clear how this influences the derivatives of the PV curve. We have assumed that differences in vulnerability of the lung

parenchyma to cigarette smoke influence the measured loss of elastic recoil more than the amount of cigarette smoke exposure.

In patients with α_1 -antitrypsin deficiency, Cheung et al³⁶ found a relationship between the loss of elastic recoil and maximal airway narrowing (plateau). It should be noted that their patient group was selective; five of eight patients had an FEV₁ > 80% of predicted, patients were clinically stable, and patients were ex-smokers or nonsmokers. These patients seemingly had only parenchymal disease. The effect of the involvement of airways disease was shown in a study by Eidelman et al.¹³ They described different patterns of mechanical abnormalities between smoking and nonsmoking patients with α_1 -antitrypsin deficiency. In COPD patients, especially in those who smoke, it is likely that there are both parenchymal and airway changes. In our study and in the study by Koyama et al³⁷, no significant correlations were found among indexes of the PV curve, on the one hand, and BHR, on the other hand. This means either that PV curves do not represent elastic recoil changes or that BHR is also influenced by airway pathology. There are several arguments that support the last mechanism. First, as discussed above, indexes of PV curves have been found to correlate with pathologic assessment of lung parenchyma. Second, the significant correlations among the different indexes of the PV curve, and between elasticity and KCO, indicate that our results are a good reflection of the loss of elastic recoil of the lung. Third, there were significant relationships between the determinant of airways obstruction (FEV₁) and PC₂₀ (Table 3).

In the present study, not only were the PC₂₀ for histamine and the PC₂₀ for methacholine correlated with the FEV₁ percent predicted, but also with reactivity. The first correlation was reported elsewhere^{2,8,9} and was found also by Cheung et al³⁶ and Koyama et al.³⁷ This indicates that the definition of PC₂₀ as a 20% fall of the starting FEV₁ makes the outcome highly dependent on measurement of FEV₁ in patients with a low FEV₁. Our finding that reactivity (the slope of the dose-response curve) is steeper at a lower FEV₁ percent predicted, indicates that reactivity also was hampered by the way in which the response is expressed. This appeared to be distinct for the plateau value, which was not correlated with the starting FEV₁ (Table 3). The clinical significance of the level of a plateau value is that it is a measure of the maximal acute bronchoconstriction that can be provoked in an individual. The application of the plateau value in combination with the PC₂₀ for methacholine has been suggested for the distinction between asthma and COPD.¹ While BHR can be found both in patients with asthma and

patients with COPD when considering PC₂₀, the plateau value usually is not reached in patients with moderately severe or severe asthma. In our study of patients with COPD who have moderately severe BHR, the plateau was reached in the majority of the patients, but not in all. It appears, therefore, that the estimation of the plateau does not always provide a clear distinction between asthma and COPD.

Because none of the indexes of BHR is related to any of the functional data of lung elasticity or CO transfer in COPD patients who smoke, airway pathology determines the response to methacholine at least to such an extent that it overrules a possible correlation with parenchymal destruction. The nature and extent of airways disease seem to be more important for the occurrence of BHR in patients with COPD than does parenchymal pathology. Taylor et al³⁸ have compared PC₂₀ for methacholine *in vivo* with the function of bronchial smooth muscle strips from surgical specimens. No correlation was found, which led to their conclusion that smooth muscle pathophysiologic changes were not responsible for BHR in COPD. One other study provided evidence that BHR in patients with emphysema is related to differences among types of emphysema and to the cell infiltrate in the airway walls.³⁹

In conclusion, we found no relationship between the impairment of lung parenchymal structure, either from PV curves or CO diffusion, and indexes of BHR. Nonspecific BHR in COPD patients who smoke is determined by small airway pathology to such an extent that it overrules a possible correlation with parenchymal impairment. The combination of our findings with those from clinicopathologic studies suggests that the plateau value (maximal airway constriction) is a better indicator of small airways pathologic changes than are PC₂₀ and reactivity.

ACKNOWLEDGMENT: The authors thank J. P. Dekker-Oostrom, K. van der Velden-van Etten, and L. Verdooren for their technical assistance.

REFERENCES

- 1 Kerrebijn KF, ed. Similarities and discrepancies between asthma and chronic obstructive pulmonary disease: a symposium; October 19–21, 1989, Lunteren, The Netherlands. *Am Rev Respir Dis* 1991; 143:1419–1472
- 2 Yan K, Salome CM, Woolcock AJ. Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1985; 132:25–29
- 3 Tashkin DP, Altose MD, Bleeker ER, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. *Am Rev Respir Dis* 1992; 145:301–310
- 4 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. *Eur Respir J* 1995; 8:1398–1420
- 5 Postma DS, De Vries K, Koëter GH, et al. Independent influence of reversibility of airflow obstruction and non-specific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. *Am Rev Respir Dis* 1986; 134:176–180
- 6 O'Byrne PM, Ramsdale EH, Hargreave FE. Isocapnic hyperventilation for measuring airway hyperresponsiveness in asthma and in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1991; 143:1444–1445
- 7 Ramsdale EH, Morris MM, Roberts RS, et al. Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis. *Thorax* 1985; 40:422–426
- 8 Ramsdale EH, Morris MM, Roberts RS, et al. Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. *Thorax* 1984; 39:912–918
- 9 Verma VK, Cockcroft DW, Dosman JA. Airway responsiveness to inhaled histamine in chronic obstructive airways disease: chronic bronchitis vs emphysema. *Chest* 1988; 94:457–461
- 10 Paré PD, Brooks LA, Bates J, et al. Exponential analysis of the lung pressure-volume curve as a predictor of pulmonary emphysema. *Am Rev Respir Dis* 1982; 126:54–61
- 11 Petty TL, Silvers GW, Stanford RE. Mild emphysema is associated with reduced elastic recoil and increased lung size but not with air-flow limitation. *Am Rev Respir Dis* 1987; 136:867–871
- 12 Osborne S, Hogg JC, Wright JL, et al. Exponential analysis of the pressure-volume curve: correlation with mean linear intercept and emphysema in human lungs. *Am Rev Respir Dis* 1988; 137:1083–1088
- 13 Eidelman DH, Ghezzi H, Kim WD, et al. Pressure-volume curves in smokers. Comparison with alpha-1-antitrypsin deficiency. *Am Rev Respir Dis* 1989; 139:1452–1458
- 14 Silvers GW, Petty TL, Stanford RE. Elastic recoil changes in early emphysema. *Thorax* 1980; 35:490–495
- 15 Gugger M, Gould G, Sudlow MF, et al. Extent of pulmonary emphysema in man and its relation to the loss of elastic recoil. *Clin Sci (Colch)* 1991; 80:353–358
- 16 Berend N, Woolcock AJ, Marlin GE. Correlation between the function and structure of the lung in smokers. *Am Rev Respir Dis* 1979; 119:695–705
- 17 Eda S, Kubo K, Fujimoto K, et al. The relations between expiratory chest CT using helical CT and pulmonary function tests in emphysema. *Am J Respir Crit Care Med* 1997; 155:1290–1294
- 18 Morrison NJ, Abboud RT, Ramadan F, et al. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema. *Am Rev Respir Dis* 1989; 139:1179–1187
- 19 Sterk PJ, Bel EH. Bronchial hyperresponsiveness: the need for a distinction between hypersensitivity and excessive airway narrowing. *Eur Respir J* 1989; 2:267–274
- 20 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1995; 152(suppl):S77–S120
- 21 Quanjer PhH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. *Eur Respir J* 1993; 6(suppl 16):5–40
- 22 Cotes JE, Chinn DJ, Quanjer PhH, et al. Standardization of the measurement of transfer factor (diffusing capacity): report of working party standardization of lung function tests, European Community for Steel and Coal; official statement of the European Respiratory Society. *Eur Respir J* 1993; 6(suppl 16):41–52

- 23 Cockcroft DW, Killian DN, Mellon JJA, et al. Bronchial reactivity to inhaled histamine: a method and clinical survey. *Clin Allergy* 1977; 7:235–243
- 24 Sterk PJ, Fabbri LM, Quanjer PhH, et al. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. *Eur Respir J* 1993; 6(suppl 16):53–83
- 25 Juniper EF, Frith PA, Dunnett C, et al. Reproducibility and comparison of responses to inhaled histamine and methacholine. *Thorax* 1978; 33:705–710
- 26 Aerts JGJV, Bogaard JM, Overbeek SE, et al. Extrapolation of methacholine log-dose response curves with a cumulative gaussian distribution function. *Eur Respir J* 1994; 7:895–900
- 27 Bogaard JM, Overbeek SE, Verbraak AFM, et al. Pressure-volume analysis of the lung with an exponential and linear-exponential model in asthma and COPD. *Eur Respir J* 1995; 8:1525–1531
- 28 Gibson GJ, Pride NB, Davis J, et al. Exponential description of the static pressure-volume curve of normal and diseased lungs. *Am Rev Respir Dis* 1979; 120:799–811
- 29 Yernault J-C, Nosedá A, Van Muylem A, et al. Variability in lung elasticity measurements in normal humans. *Am Rev Respir Dis* 1983; 128:816–819
- 30 DuToit JI, Woolcock AJ, Salome CM, et al. Characteristics of bronchial hyperresponsiveness in smokers with chronic airflow limitation. *Am Rev Respir Dis* 1986; 134:498–501
- 31 Moreno RH, Hogg JC, Paré PD. Mechanics of airway narrowing. *Am Rev Respir Dis* 1986; 133:1171–1180
- 32 Greaves IA, Colebatch HJ. Elastic behavior and structure of normal and emphysematous lungs post mortem. *Am Rev Respir Dis* 1980; 121:127–136
- 33 McCuaig KE, Vessal S, Coppin K, et al. Variability in measurements of pressure-volume curves in normal subjects. *Am Rev Respir Dis* 1985; 131:656–658
- 34 Yernault JC, Baran D, Englert M. Effect of growth and aging on the static mechanical lung properties. *Bull Eur Physio-pathol Respir* 1977; 13:777–788
- 35 Mitchell RS, Stanford RE, Johnson JM, et al. The morphologic features of the bronchi, bronchioles and alveoli in chronic airway obstruction: a clinicopathologic study. *Am Rev Respir Dis* 1976; 114:137–145
- 36 Cheung D, Schot R, Zwinderman AH, et al. Relationship between loss in parenchymal elastic recoil pressure and maximal airway narrowing in subjects with α_1 -antitrypsin deficiency. *Am J Respir Crit Care Med* 1996; 155:135–140
- 37 Koyama H, Nishimura K, Ikeda A, et al. Influence of baseline airway calibre and pulmonary emphysema on bronchial responsiveness in patients with chronic obstructive pulmonary disease. *Respir Med* 1996; 90:323–328
- 38 Taylor SM, Paré PD, Armour CL, et al. Airway reactivity in chronic obstructive pulmonary disease: failure of *in vivo* methacholine responsiveness to correlate with cholinergic, adrenergic, or nonadrenergic responses *in vitro*. *Am Rev Respir Dis* 1985; 132:30–35
- 39 Finkelstein R, Ma HD, Ghezzi H, et al. Morphometry of small airways in smokers and its relation to emphysema type and hyperresponsiveness. *Am J Respir Crit Care Med* 1995; 152:267–276

Influence of Lung Parenchymal Destruction on the Different Indexes of the Methacholine Dose-Response Curve in COPD Patients

Gert T. Verhoeven, Anton F.M. Verbraak, Sandra Boere-van der Straat, Henk C. Hoogsteden and Jan M. Bogaard
Chest 2000;117:984-990
DOI: 10.1378/chest.117.4.984

This information is current as of December 4, 2006

Updated Information & Services	Updated information and services, including high-resolution figures, can be found at: http://www.chestjournal.org/cgi/content/full/117/4/984
References	This article cites 39 articles, 13 of which you can access for free at: http://www.chestjournal.org/cgi/content/full/117/4/984#BIBL
Citations	This article has been cited by 1 HighWire-hosted articles: http://www.chestjournal.org/cgi/content/full/117/4/984#otherarticles
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.chestjournal.org/misc/reprints.shtml
Reprints	Information about ordering reprints can be found online: http://www.chestjournal.org/misc/reprints.shtml
Email alerting service	Receive free email alerts when new articles cite this article sign up in the box at the top right corner of the online article.
Images in PowerPoint format	Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online article figure for directions.

